You are here: Annual Meeting / Past Events / 2010 / Programme / Tuesday 13/4

ECNP School of Neuropsychopharmacology

Call for Applications
Participants at the SCNP 2011 meeting in Oslo are eligible to apply for the third course of the ECNP School of Neuropsychopharmacology. This course will be held from 3-8 July 2011 in Oxford, United Kingdom. SCNP will nominate 2-3 delegates that will attend the course free of charge and have their travel and accommodation expenses subsidized.

Deadline for application is April 1st 2011.

Who can apply?
The candidates would be qualified psychiatrists within 5 years of receiving their defining qualification and are likely to become key leaders of the speciality in the individual countries.

Guidelines to applicants
Applications should be submitted by e-mail to the scientific secretariat: ecnp_school(at)scnp.dk

The application form can be found here.


The Congress venue is situated in the centre of Oslo, only 100 meters from the Central Station and the Express train from Oslo Lufthavn Gadermoen. The Airport shuttle bus stops in front of the hotel. It is close to Oslo's finest shopping, sightseeing and entertainment. The congress venue also has indoor parking facilities if you arrive by car.

DRIVING DIRECTIONS

09.00-9.40 PLENARY SESSION

SCNP 2010 - LECTURE
Moderator: Jesper Ekelund (Helsinki)

Serotonin in brain: what is it good for? Lessons learnt, e.g., from the treatment of premenstrual dysphoria and panic disorder
Elias Eriksson (Gothenburg)

09.45-10.30   PARALLEL SESSIONS

I. Clinical use of pharmacogenetics
Moderators: Ole A. Andreassen (Oslo) & Andres Magnusson (Reykjavik)

The cytochrome P450 system in clinical practice
Helge Refsum (Oslo)

Lipid genes and side effects 
Vidar M. Steen (Bergen)

Pharmacogenetic testing in healthcare - update on recent applications
Erik Eliasson (Stockholm)

II. ECNP Educational Symposium ? Drugs in development
Moderators: Arvid Carlsson (Gothenburg) & Hans-Jürgen Möller (Munich)

Dopamine stabilizers - an update

Arvid Carlsson (Gothenburg)

mGlu2/3 receptor agonists and other drugs in the pipeline 
Ole Kristian Kleivenes (Eli Lilly, Scandinavia)

New treatment options for alcohol addiction
Marcus Heilig (Washington, DC)

Potential utility of immunomodulators in psychiatry
Robert Dantzer (Urbana, USA)

10.30-11.00 COFFEE BREAK

11.00-12.30   PARALLEL SESSIONS 

I. Psychosis in the elderly 
Moderators: Tove Gunnarsson (Stockholm) & Dag Årsland (Stavanger) 

Psychosis in dementia
Dag Årsland (Stavanger) 

Confessions from a clinician
Ingvar Karlsson (Gothenburg)

Antipsychotic drugs in elderly: problems and solutions
Knut Engedal (Oslo)

Non alcholic delirium, a neglected disease
Kirsten Abelskov (Aarhus)

II. Psychosomatic disorders: from neurobiology to treatment.
Moderators: Ulrik F. Malt (Helsinki) & Per Fink (Aarhus)

Pharmacological treatment of psychosomatic disorders
Ulrik F. Malt (Oslo)

Recent advances in understanding of functional disorders 
Per Fink (Aarhus)

Management of functional somatic syndromes
Peter Henningsen (München) 

The STreSS-trial: an example of a novel treatment approach
Andreas Schröder (Aarhus)

12.30-13.30  LUNCH 

13.30-15.00  PLENARY SESSION

SCNP YOUNG SCIENTIST SYMPOSIUM 
Moderators: Ole A. Andreassen (Oslo) and Gregers Wegener (Aarhus)

Speakers to be selected from abstracts submitted

15.00-15.30 COFFEE BREAK

15.30-17.00 ASTRA ZENECA SATELLITE SYMPOSIUM

Antipsychotic and antidepressant drug indications revisited
Moderators: Torgny H. Svensson (Stockholm) & Hans-Jürgen Möller (Munich)

Combined use of antidepressant and antipsychotic drugs: Preclinical aspects    Torgny H. Svensson (Stockholm)

NET-inhibition and and the clinical profile of quetiapine
Svante Nyberg (Södertälje)

Combined use of antidepressant and and antipsychotic drugs. Clinical aspects
Hans-Jürgen Möller (Munich)

Combined use of antidepressant and antipsychotic drugs. Implications for drug discovery and development
Alan Cross (Wilmington, USA)

17.00-18.30 POSTER SESSION. Refreshments

18.30- 51ST  CONGRESS DINNER. DETAILS TO BE ANNOUNCED